Cardiology

Newer anticoagulants linked to gastrointestinal bleeding

(HealthDay)—Patients taking the new generation of oral anticoagulants appear to have a higher risk of gastrointestinal bleeding compared with standard care, particularly when treated for venous thrombosis or acute coronary ...

Medications

Xarelto's approval expanded

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

Cardiology

Stroke risk high when anti-clotting drugs stopped

Some patients with irregular heartbeats who are taken off anti-clotting medication face a high risk of stroke or blood clotting within a month, according to new research presented at the American Heart Association's Emerging ...

Cardiology

Levetiracetam may reduce anticoagulation effect of rivaroxaban

Levetiracetam, a commonly used medication to prevent seizures, may reduce the anticoagulation effect of oral rivaroxaban in humans. As such, clinicians should measure direct oral anticoagulant plasma levels during treatment. ...

Neuroscience

Warfarin, rivaroxaban similarly safe, effective

(HealthDay)—For cases of mild atrial fibrillation (AF)-related acute ischemic stroke, rivaroxaban and warfarin are similarly safe and effective at preventing recurrent stroke, according to a study published online Sept. ...

Medications

GI bleeding up for new users of rivaroxaban

Rivaroxaban is associated with increased rates of gastrointestinal bleeding (GIB) compared with other direct oral anticoagulants, according to a study published online Oct. 12 in the Annals of Internal Medicine.

page 2 from 4